{"id":"W2144896295","doi":"10.1016/s0140-6736(09)60447-5","title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","year":2009,"lang":"en","type":"article","venue":"The Lancet","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1020,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"AstraZeneca","keywords":"Rosuvastatin; Medicine; Internal medicine; Rosuvastatin Calcium; Cholesterol; Reduction (mathematics); Ldl cholesterol; Cardiology; Prospective cohort study; C-reactive protein; Jupiter (rocket family); Cardiovascular event; Inflammation; Disease; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01833056986093243,"score_gpt":0.2832555200015539,"score_spread":0.2649249501406215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}